Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J., June 21, 2024 CRANBURY, N.J., June 21, 2024 /PRNewswire/ -- Palatin Technologies...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire CRANBURY, N.J., June 20, 2024...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire CRANBURY, N.J., June 12, 2024 Co-Administration Phase 2 study of bremelanotide with tirzepatide...
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., May 15, 2024 Positive Phase 3 PL9643 MELODY-1 Pivotal Study...
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J., May 9, 2024 CRANBURY, N.J., May 9, 2024 /PRNewswire/...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire CRANBURY, N.J., May 2, 2024 Phase 2...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR...
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 PR Newswire CRANBURY, N.J...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.11 | 5.97826086957 | 1.84 | 1.97 | 1.78 | 69162 | 1.86052664 | CS |
4 | 0.08 | 4.27807486631 | 1.87 | 2.13 | 1.74 | 82463 | 1.90997274 | CS |
12 | 0.2 | 11.4285714286 | 1.75 | 2.88 | 1.66 | 391033 | 2.01059718 | CS |
26 | -2.25 | -53.5714285714 | 4.2 | 5.65 | 1.46 | 454395 | 2.65349767 | CS |
52 | -0.19 | -8.8785046729 | 2.14 | 5.65 | 1.43 | 294197 | 2.59391314 | CS |
156 | 1.4016 | 255.579868709 | 0.5484 | 8.6 | 0.1811 | 1192125 | 0.79970397 | CS |
260 | 0.82 | 72.5663716814 | 1.13 | 8.6 | 0.1811 | 1662939 | 0.7622939 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.